UBS Group
ICCC icon

UBS Group’s ImmuCell ICCC Stock Holding History

UBS Group’s Portfolio ICCC Stock Details ICCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1K Sell
1,000
-113
-10% -$998 ﹤0.01% 8568
2026
Q1 		$7.04K Sell
1,113
-498
-31% -$3.19K ﹤0.01% 8628
2025
Q4 		$9.91K Buy
1,611
+611
+61% +$3.6K ﹤0.01% 8253
2025
Q3 		$6.25K Sell
1,000
-7,391
-88% -$46.7K ﹤0.01% 8793
2025
Q2 		$58.4K Sell
8,391
-8,500
-50% -$49.6K ﹤0.01% 7652
2025
Q1 		$80.9K Buy
16,891
+4,311
+34% +$22.1K ﹤0.01% 7208
2024
Q4 		$64.8K Sell
12,580
-3,362
-21% -$13.4K ﹤0.01% 7139
2024
Q3 		$57.9K Buy
15,942
+13,267
+496% +$51.6K ﹤0.01% 6723
2024
Q2 		$13K Sell
2,675
-1,775
-40% -$8.54K ﹤0.01% 7574
2024
Q1 		$23.6K Buy
4,450
+2,950
+197% +$15.2K ﹤0.01% 6852
2023
Q4 		$7.63K Sell
1,500
-96
-6% -$468 ﹤0.01% 7613
2023
Q3 		$8.52K Sell
1,596
-104
-6% -$528 ﹤0.01% 7182
2023
Q2 		$8.5K Sell
1,700
-96
-5% -$491 ﹤0.01% 7235
2023
Q1 		$9.18K Buy
1,796
+296
+20% +$1.92K ﹤0.01% 7671
2022
Q4 		$9.15K Hold
1,500
– – ﹤0.01% 8686
2022
Q3 		$11K Sell
1,500
-1,148
-43% -$9.38K ﹤0.01% 8299
2022
Q2 		$23K Buy
2,648
+682
+35% +$5.91K ﹤0.01% 6703
2022
Q1 		$19K Sell
1,966
-382
-16% -$3.3K ﹤0.01% 7509
2021
Q4 		$19K Hold
2,348
– – ﹤0.01% 7904
2021
Q3 		$22K Buy
2,348
+248
+12% +$2.35K ﹤0.01% 7061
2021
Q2 		$20K Hold
2,100
– – ﹤0.01% 7331
2021
Q1 		$20K Sell
2,100
-1,267
-38% -$11.9K ﹤0.01% 7382
2020
Q4 		$21K Buy
3,367
+1,051
+45% +$6.12K ﹤0.01% 6914
2020
Q3 		$12K Buy
2,316
+216
+10% +$1.2K ﹤0.01% 6701
2020
Q2 		$10K Hold
2,100
– – ﹤0.01% 7013
2020
Q1 		$8K Sell
2,100
-2,924
-58% -$14.4K ﹤0.01% 7077
2019
Q4 		$26K Sell
5,024
-1,820
-27% -$9.38K ﹤0.01% 6731
2019
Q3 		$38K Buy
6,844
+1,533
+29% +$8.96K ﹤0.01% 6349
2019
Q2 		$35K Buy
5,311
+1,311
+33% +$8.32K ﹤0.01% 6210
2019
Q1 		$25K Hold
4,000
– – ﹤0.01% 6102
2018
Q4 		$28K Sell
4,000
-250
-6% -$1.93K ﹤0.01% 6529
2018
Q3 		$35K Sell
4,250
-1,528
-26% -$11K ﹤0.01% 6429
2018
Q2 		$39K Buy
5,778
+716
+14% +$5.14K ﹤0.01% 6191
2018
Q1 		$35K Buy
5,062
+1,062
+27% +$7.78K ﹤0.01% 5982
2017
Q4 		$35K Hold
4,000
– – ﹤0.01% 6123
2017
Q3 		$26K Sell
4,000
-1,594
-28% -$10.4K ﹤0.01% 6268
2017
Q2 		$41K Buy
5,594
+3,143
+128% +$18.7K ﹤0.01% 5797
2017
Q1 		$14K Sell
2,451
-3,275
-57% -$18.8K ﹤0.01% 6403
2016
Q4 		$34K Buy
5,726
+1,426
+33% +$8.68K ﹤0.01% 6137
2016
Q3 		$33K Sell
4,300
-151
-3% -$1.1K ﹤0.01% 5836
2016
Q2 		$31K Sell
4,451
-317
-7% -$2.14K ﹤0.01% 5904
2016
Q1 		$32K Buy
4,768
+1,802
+61% +$12K ﹤0.01% 5839
2015
Q4 		$22K Buy
2,966
+3
+0.1% +$21 ﹤0.01% 6654
2015
Q3 		$18K Buy
2,963
+663
+29% +$5.41K ﹤0.01% 6806
2015
Q2 		$18K Sell
2,300
-238
-9% -$1.64K ﹤0.01% 6970
2015
Q1 		$16K Buy
2,538
+1,256
+98% +$7.92K ﹤0.01% 7204
2014
Q4 		$6K Buy
+1,282
New +$6.11K ﹤0.01% 8831

Other funds holding ICCC

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
S
Steadtrust Allen, Texas $198M AUM 99.37% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

UBS Group's ICCC Position: Q2 2026 in Review

UBS Group reduced its ImmuCell (ICCC) stake by 10% in Q2 2026, selling an estimated $998 and leaving 1,000 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #8568.

UBS Group first reported a position in ICCC in Q4 2014 and has held it in 47 quarters since. The position peaked at $80.9K in Q1 2025. 30 funds tracked by Wall St. Rank hold ICCC as of Q2 2026.

  • UBS Group held 1,000 shares of ImmuCell worth $10.1K as of Q2 2026.
  • UBS Group sold 113 ImmuCell shares in Q2 2026, an estimated $998.
  • ImmuCell made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8568 holding.
  • UBS Group first reported a position in ImmuCell in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's ImmuCell position peaked at $80.9K in Q1 2025.
  • 30 funds tracked by Wall St. Rank held ImmuCell as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.